Pentadeca Arginate vs TB-500
Side-by-side comparison of Pentadeca Arginate, TB-500 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | Pentadeca Arginate Pentadeca Arginate (PDA) — BPC-157 Arginine Variant Recovery | TB-500 Thymosin Beta-4 Synthetic Analogue Recovery |
|---|---|---|
| Basics | ||
| Molecular type | Pentadecapeptide Arginine Analogue | Thymic Peptide Analogue |
| Amino acids | 15 | 43 |
| Molecular weight | 1,476.6 Da | 4,921 Da |
| Half-life | ~4–6 hrs (estimated) | Long-acting (days) |
| Route(s) | Subcutaneous, Intramuscular, Oral (research) | Subcutaneous, Intramuscular |
| Mechanism & Research | ||
| Primary mechanism | PDA shares BPC-157's primary mechanism of action: nitric oxide (NO) synthase upregulation, VEGFR2-mediated angiogenesis, and connective tissue repair signalling. The arginine modification may further amplify NO pathway a… | TB-500's primary mechanism involves binding to G-actin (monomeric actin) through its conserved LKKTETQ sequence. By sequestering actin, it regulates cytoskeletal dynamics in ways that promote cell migration — a critical … |
| Research status | Research Compound | Research Compound |
| Evidence summary | PDA is a newer research compound with a smaller published evidence base than BPC-157. Most researchers extrapolate from BPC-157's extensive preclinical data given the structural and mechanistic similarity. Direct compara… | TB-500 research spans cardiac regeneration, wound healing, hair follicle regeneration, and musculoskeletal repair. Most data is preclinical. Phase 1/2 trials with native Thymosin Beta-4 for cardiac indications have been … |
| Protocol & Dosing | ||
| Typical dose | 200–500 mcg per injection | 5–10 mg per injection |
| Frequency | Once or twice daily | 2x per week (loading), then weekly |
| Duration | 4–12 weeks | 4–8 weeks |
| Timing | Near injury site when possible; any time | No specific timing requirement |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S0) | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | BPC-157, TB-500, GHK-Cu | BPC-157, GHK-Cu, Thymosin Alpha-1 |
| Full profile | Read full Pentadeca Arginate profile → | Read full TB-500 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.